Perspectives of further reduction in cholesterol by means of PCSK9 blockade

Abstract

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a newly discovered member of the proprotein convertase family.

Keywords

• dyslipidemia
• hypolipidemic treatment
• cardiovascular risk
• atherosclerosis